Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial with 120 mcg Dexmedetomidine dose to evaluate safety in at-home setting

Next Previous
Trial Profile

A Phase 3 trial with 120 mcg Dexmedetomidine dose to evaluate safety in at-home setting

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 22 Apr 2024 According to a BioXcel Therapeutics media release, the company announced additional details regarding the planned design of this outpatient trial.the Company expects to enroll approximately 30 patients in a separate study to evaluate the correlation between patient-reported or informant-reported efficacy with trained rater-reported efficacy using Positive and Negative Syndrome Scale-Excitatory Component (PEC) measurements.
  • 12 Mar 2024 According to a BioXcel Therapeutics media release, company expects to provide further guidance regarding program plans following receipt of final meeting minutes from FDA.
  • 11 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top